[PDF][PDF] RAS and ROS in rhabdomyosarcoma
M Zhang, CM Linardic, DG Kirsch - Cancer Cell, 2013 - cell.com
M Zhang, CM Linardic, DG Kirsch
Cancer Cell, 2013•cell.comThe 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients
presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues
performed whole-genome and RNA sequencing on human rhabdomyosarcoma and
identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk
embryonal rhabdomyosarcoma.
presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues
performed whole-genome and RNA sequencing on human rhabdomyosarcoma and
identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk
embryonal rhabdomyosarcoma.
The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.
cell.com
